Modification of Automatic Synthesis of [18F]Fluoromisonidazole on a GE TracerLAB Fx F-N Synthesis Module


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

A procedure for preparing 1-(2-hydroxy-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]fluoromisonidazole, [18F]FMISO) on a commercially available GE TracerLAB Fx F-N synthesis module was developed. The product obtained meets all the requirements of the European Pharmacopoeia (8th ed.) for clinical use. Its decay-corrected radiochemical yield is 59 ± 4% (n = 5).

About the authors

D. O. Antuganov

Almazov Northwest Federal Medical Research Center

Author for correspondence.
Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

D. V. Ryzhkova

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

T. A. Zykova

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

V. V. Timofeev

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

Yu. O. Antuganova

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

K. Yu. Timofeeva

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

O. P. Samburov

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

M. P. Zykov

Almazov Northwest Federal Medical Research Center

Email: antuganov_do@almazovcentre.ru
Russian Federation, ul. Akkuratova 2, St. Petersburg, 197341

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Pleiades Publishing, Inc.